Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes various products for patients suffering from pain. It provides DETERx platform technology that is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods of abuse and tampering, including chewing, crushing, and/or dissolving. The company offers Xtampza, an abuse-deterrent, extended-release, oral formulation of oxycodone for opioid medication. It is also developing Onsolis, a transmucosal immediate-release fentanyl film indicated for the management of breakthrough pain in cancer patients 18 years of age and older. In addition, the company offers Nucynta ER, an extended release formulation of tapentadol for the management of pain severe enough to require daily, around-the-clock, long term opioid treatment, such as neuropathic pain related to diabetic peripheral neuropathy in adults; and Nucynta IR, an immediate release formulation of tapentadol that is indicated for the management of moderate to severe acute pain in adults. Further, it is developing COL-195, an abuse-deterrent, extended-release hydrocodone for the treatment of chronic pain; COL-172, an abuse-deterrent, extended-release oxymorphone for the treatment of chronic pain; and COL-171, a proprietary preclinical DETERx extended-release, abuse-deterrent methylphenidate formulation for attention deficit hyperactivity disorder (ADHD), as well as COL-196, a morphine formulation. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone781-713-3699
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$28.48 million
Profitability
Miscellaneous
Employees250
Next Earnings Date2/27/2019 (Confirmed)
OptionableOptionable
Collegium Pharmaceutical (NASDAQ:COLL) Frequently Asked Questions
What is Collegium Pharmaceutical's stock symbol?
Collegium Pharmaceutical trades on the NASDAQ under the ticker symbol "COLL."
How were Collegium Pharmaceutical's earnings last quarter?
Collegium Pharmaceutical Inc (NASDAQ:COLL) announced its quarterly earnings results on Wednesday, August, 8th. The specialty pharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.42) by $0.02. The specialty pharmaceutical company earned $73.10 million during the quarter, compared to analyst estimates of $72.21 million. Collegium Pharmaceutical had a negative return on equity of 70.06% and a negative net margin of 30.13%. The company's revenue was up 1930.6% compared to the same quarter last year. View Collegium Pharmaceutical's Earnings History.
When is Collegium Pharmaceutical's next earnings date?
What price target have analysts set for COLL?
6 equities research analysts have issued twelve-month price objectives for Collegium Pharmaceutical's stock. Their forecasts range from $27.00 to $35.00. On average, they expect Collegium Pharmaceutical's share price to reach $32.40 in the next twelve months. This suggests a possible upside of 114.7% from the stock's current price. View Analyst Price Targets for Collegium Pharmaceutical.
What is the consensus analysts' recommendation for Collegium Pharmaceutical?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Collegium Pharmaceutical in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Collegium Pharmaceutical.
What are Wall Street analysts saying about Collegium Pharmaceutical stock?
Here are some recent quotes from research analysts about Collegium Pharmaceutical stock:
- 1. According to Zacks Investment Research, "Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company's product candidate consists of COL-195, COL-196, COL-171, COL-003 and COL-172 which are in different clinical trial. It developed a formulation platform technology, DETERx, for the treatment of chronic pain. Collegium Pharmaceutical Inc. is based in CUMBERLAND, United States. " (1/23/2019)
- 2. Cantor Fitzgerald analysts commented, ". We are reiterating our Overweight rating and 12-month price target of $35 post COLL issuing 2019 revenue guidance below FactSet consensus, and our estimates. We remain positive on the long-term growth potential of Xtampza, and we believe that Xtampza will replace OxyContin as the largest branded oxycodone ER product over time with COLL building itself into one of the leading specialist pain companies." (1/7/2019)
Has Collegium Pharmaceutical been receiving favorable news coverage?
News stories about COLL stock have been trending positive on Thursday, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Collegium Pharmaceutical earned a coverage optimism score of 2.3 on InfoTrie's scale. They also assigned media headlines about the specialty pharmaceutical company a news buzz of 9.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the stock's share price in the near term.
Who are some of Collegium Pharmaceutical's key competitors?
Some companies that are related to Collegium Pharmaceutical include Endocyte (ECYT), Enanta Pharmaceuticals (ENTA), Supernus Pharmaceuticals (SUPN), Insmed (INSM), Xencor (XNCR), The Medicines (MDCO), PTC Therapeutics (PTCT), Biohaven Pharmaceutical (BHVN), Mallinckrodt (MNK), AnaptysBio (ANAB), Myokardia (MYOK), Arrowhead Pharmaceuticals (ARWR), Pacira Pharmaceuticals (PCRX), Opko Health (OPK) and Zai Lab (ZLAB).
What other stocks do shareholders of Collegium Pharmaceutical own?
Who are Collegium Pharmaceutical's key executives?
Collegium Pharmaceutical's management team includes the folowing people:
- Mr. Michael T. Heffernan, Co-Founder & Chairman (Age 55)
- Mr. Joseph J. Ciaffoni, Pres, CEO & Director (Age 48)
- Mr. Paul J. Brannelly, Exec. VP & CFO (Age 46)
- Dr. Alison B. Fleming, Exec. VP & Chief Technology Officer (Age 44)
- Ms. Alex Dasalla, Head of Investor Relations
When did Collegium Pharmaceutical IPO?
(COLL) raised $75 million in an initial public offering (IPO) on Thursday, May 7th 2015. The company issued 5,800,000 shares at $12.00-$14.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Wells Fargo Securities and Needham & Company were co-managers.
Who are Collegium Pharmaceutical's major shareholders?
Collegium Pharmaceutical's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Macquarie Group Ltd. (8.30%), BlackRock Inc. (7.88%), Millennium Management LLC (3.93%), Sectoral Asset Management Inc (3.48%), Massachusetts Financial Services Co. MA (2.00%) and Perceptive Advisors LLC (1.34%). Company insiders that own Collegium Pharmaceutical stock include Alison B Fleming, Joseph Ciaffoni, Longitude Capital Partners, Ll, Michael Thomas Heffernan and Paul Brannelly. View Institutional Ownership Trends for Collegium Pharmaceutical.
Which institutional investors are selling Collegium Pharmaceutical stock?
COLL stock was sold by a variety of institutional investors in the last quarter, including Sectoral Asset Management Inc, Prudential Financial Inc., Northern Trust Corp, Squarepoint Ops LLC, Hamilton Lane Advisors LLC, Strs Ohio, United Services Automobile Association and Raymond James & Associates. Company insiders that have sold Collegium Pharmaceutical company stock in the last year include Alison B Fleming, Joseph Ciaffoni, Michael Thomas Heffernan and Paul Brannelly. View Insider Buying and Selling for Collegium Pharmaceutical.
Which institutional investors are buying Collegium Pharmaceutical stock?
COLL stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Perceptive Advisors LLC, Macquarie Group Ltd., BlackRock Inc., Dimensional Fund Advisors LP, 1492 Capital Management LLC, Citigroup Inc. and Opaleye Management Inc.. View Insider Buying and Selling for Collegium Pharmaceutical.
How do I buy shares of Collegium Pharmaceutical?
Shares of COLL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Collegium Pharmaceutical's stock price today?
One share of COLL stock can currently be purchased for approximately $15.09.
How big of a company is Collegium Pharmaceutical?
Collegium Pharmaceutical has a market capitalization of $501.74 million and generates $28.48 million in revenue each year. The specialty pharmaceutical company earns $-74,860,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis. Collegium Pharmaceutical employs 250 workers across the globe.
What is Collegium Pharmaceutical's official website?
How can I contact Collegium Pharmaceutical?
Collegium Pharmaceutical's mailing address is 100 Technology Center Drive, Stoughton MA, 02072. The specialty pharmaceutical company can be reached via phone at 781-713-3699.
MarketBeat Community Rating for Collegium Pharmaceutical (NASDAQ COLL)
MarketBeat's community ratings are surveys of what our community members think about Collegium Pharmaceutical and other stocks. Vote "Outperform" if you believe COLL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe COLL will underperform the S&P 500 over the long term. You may vote once every thirty days.
